首页 > 最新文献

Journal of Cardiovascular Pharmacology最新文献

英文 中文
Association Between the Neutrophil-to-Lymphocyte Ratio and in-Stent Neoatherosclerosis and Plaque Vulnerability: An Optical Coherence Tomography Study. 中性粒细胞与淋巴细胞比率与支架内新动脉粥样硬化和斑块易损性之间的关系:光学相干断层扫描研究。
IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1097/FJC.0000000000001616
Ning Gu, Panke Chen, Xi Wang, Changyin Shen, Yi Deng, Jianling Chen, Yi Ma, Shuai Ma, Xingwei Hu, Ranzun Zhao, Bei Shi

Abstract: The aim of this study was to explore the relationship between in-stent neoatherosclerosis (ISNA) and the neutrophil-to-lymphocyte ratio (NLR) in patients with in-stent restenosis (ISR) following drug-eluting stent (DES) implantation. We divided 216 patients into 3 groups based on the NLR tertile. We performed a comparative analysis of baseline, angiographic, and features of optical coherence tomography (OCT) between the NLR groups and performed univariate and multivariate logistic regression analyses to assess the association of the NLR with ISNA and in-stent thin-cap fibroatheroma (TCFA). Patients in the third tertile NLR group had a higher incidence of ISNA and in-stent TCFA compared with those in the first tertile. Multivariate logistic regression analysis showed that the hazard ratios and 95% confidence intervals for ISNA and TCFA were 2.673 (1.257-5.684; P = 0.038) and 4.272 (1.740-10.488; P = 0.004), respectively, for patients in the highest tertile compared with those in the lowest tertile. Our study showed that an increased NLR was associated with ISNA and in-stent plaque fragility in patients with ISR following DES implantation.

摘要:本研究旨在探讨药物洗脱支架(DES)植入后支架内再狭窄(ISR)患者的支架内新动脉粥样硬化(ISNA)与中性粒细胞/淋巴细胞比值(NLR)之间的关系。我们根据 NLR tertile 将 216 例患者分为 3 组。我们对 NLR 组间的基线、血管造影和光学相干断层扫描(OCT)特征进行了比较分析,并进行了单变量和多变量逻辑回归分析,以评估 NLR 与 ISNA 和支架内薄帽纤维血管瘤(TCFA)的相关性。与第一分位数的患者相比,第三分位数NLR组患者的ISNA和支架内TCFA发生率更高。多变量逻辑回归分析显示,与最低三等分组相比,最高三等分组患者 ISNA 和 TCFA 的危险比和 95% 置信区间分别为 2.673 (1.257-5.684; P = 0.038) 和 4.272 (1.740-10.488; P = 0.004)。我们的研究表明,在植入 DES 后出现 ISR 的患者中,NLR 增加与 ISNA 和支架内斑块脆性有关。
{"title":"Association Between the Neutrophil-to-Lymphocyte Ratio and in-Stent Neoatherosclerosis and Plaque Vulnerability: An Optical Coherence Tomography Study.","authors":"Ning Gu, Panke Chen, Xi Wang, Changyin Shen, Yi Deng, Jianling Chen, Yi Ma, Shuai Ma, Xingwei Hu, Ranzun Zhao, Bei Shi","doi":"10.1097/FJC.0000000000001616","DOIUrl":"10.1097/FJC.0000000000001616","url":null,"abstract":"<p><strong>Abstract: </strong>The aim of this study was to explore the relationship between in-stent neoatherosclerosis (ISNA) and the neutrophil-to-lymphocyte ratio (NLR) in patients with in-stent restenosis (ISR) following drug-eluting stent (DES) implantation. We divided 216 patients into 3 groups based on the NLR tertile. We performed a comparative analysis of baseline, angiographic, and features of optical coherence tomography (OCT) between the NLR groups and performed univariate and multivariate logistic regression analyses to assess the association of the NLR with ISNA and in-stent thin-cap fibroatheroma (TCFA). Patients in the third tertile NLR group had a higher incidence of ISNA and in-stent TCFA compared with those in the first tertile. Multivariate logistic regression analysis showed that the hazard ratios and 95% confidence intervals for ISNA and TCFA were 2.673 (1.257-5.684; P = 0.038) and 4.272 (1.740-10.488; P = 0.004), respectively, for patients in the highest tertile compared with those in the lowest tertile. Our study showed that an increased NLR was associated with ISNA and in-stent plaque fragility in patients with ISR following DES implantation.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":"84 5","pages":"506-514"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commentary on Antithrombotic Effect of Protopanaxatriol Saponins from Panax notoginseng Using Zebrafish Model. 以斑马鱼为模型评述三七中原三七皂苷的抗血栓作用
IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1097/FJC.0000000000001621
Alfredo Caturano, Vincenzo Russo, Marcellino Monda, Celestino Sardu, Raffaele Marfella, Ferdinando Carlo Sasso
{"title":"Commentary on Antithrombotic Effect of Protopanaxatriol Saponins from Panax notoginseng Using Zebrafish Model.","authors":"Alfredo Caturano, Vincenzo Russo, Marcellino Monda, Celestino Sardu, Raffaele Marfella, Ferdinando Carlo Sasso","doi":"10.1097/FJC.0000000000001621","DOIUrl":"10.1097/FJC.0000000000001621","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"493-495"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-Thrombotic Effect of Protoparaxotriol Saponins From Panax notoginseng Using Zebrafish Model. 利用斑马鱼模型研究三七中原三七皂苷的抗血栓作用
IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1097/FJC.0000000000001604
Xin Liu, Wei Fan, Shenghua Lin, Jiayu Chen, Shanshan Zhang, Xiaobin Li, Meng Jin, Qiuxia He

Abstract: Panax notoginseng has the effect of stimulating circulation to end stasis. Our study was designed to evaluate the anti-thrombotic effect of protoparaxotriol saponins (PTS) from P. notoginseng and the involved mechanisms. A thrombosis model was constructed, and the anti-thrombotic activity of PTS was determined by erythrocyte staining, heart rate, and blood flow velocity. In addition, quantitative real-time polymerase chain reaction was used to identify changes in the expression of genes related to coagulation, inflammation, and apoptosis. PTS alleviated arachidonic acid-induced caudal vein thrombosis, restored blood flow, and increased the area of cardiac erythrocyte staining, heart rate, and blood flow velocity. It reduced the ponatinib-induced cerebral thrombus area and decreased the intensity of erythrocyte staining. The quantitative polymerase chain reaction data showed that the anti-thrombotic effect of PTS was mediated by suppression of genes related to coagulation, inflammation, and apoptosis and also involved inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathways.

三七具有活血化瘀的功效。我们的研究旨在评估三七中的原三七皂苷(PTS)的抗血栓作用及其机制。研究构建了血栓形成模型,并通过红细胞染色、心率和血流速度测定了原人参三醇皂苷的抗血栓活性。此外,还使用实时定量聚合酶链反应(qPCR)来确定凝血、炎症和细胞凋亡相关基因的表达变化。PTS缓解了花生四烯酸(AA)诱导的尾静脉血栓形成,恢复了血流量,增加了心脏红细胞染色面积、心率和血流速度。它减少了泊纳替尼诱导的脑血栓面积,降低了红细胞染色的强度。qPCR 数据显示,PTS 的抗血栓作用是通过抑制与凝血、炎症和细胞凋亡相关的基因介导的,还涉及对 NF-κB 和 PI3K/Akt 通路的抑制。
{"title":"Anti-Thrombotic Effect of Protoparaxotriol Saponins From Panax notoginseng Using Zebrafish Model.","authors":"Xin Liu, Wei Fan, Shenghua Lin, Jiayu Chen, Shanshan Zhang, Xiaobin Li, Meng Jin, Qiuxia He","doi":"10.1097/FJC.0000000000001604","DOIUrl":"10.1097/FJC.0000000000001604","url":null,"abstract":"<p><strong>Abstract: </strong>Panax notoginseng has the effect of stimulating circulation to end stasis. Our study was designed to evaluate the anti-thrombotic effect of protoparaxotriol saponins (PTS) from P. notoginseng and the involved mechanisms. A thrombosis model was constructed, and the anti-thrombotic activity of PTS was determined by erythrocyte staining, heart rate, and blood flow velocity. In addition, quantitative real-time polymerase chain reaction was used to identify changes in the expression of genes related to coagulation, inflammation, and apoptosis. PTS alleviated arachidonic acid-induced caudal vein thrombosis, restored blood flow, and increased the area of cardiac erythrocyte staining, heart rate, and blood flow velocity. It reduced the ponatinib-induced cerebral thrombus area and decreased the intensity of erythrocyte staining. The quantitative polymerase chain reaction data showed that the anti-thrombotic effect of PTS was mediated by suppression of genes related to coagulation, inflammation, and apoptosis and also involved inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathways.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"528-538"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/Parkin Pathway to Alleviate ISO-induced Cardiac Remodeling. 卡格列净通过AMPK/PINK1/PARKIN途径介导有丝分裂,从而缓解异丙肾上腺素诱导的心脏重构。
IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1097/FJC.0000000000001625
Shaolin Gong, Yuan Sui, Mengxuan Xiao, Daoyao Fu, Zhiping Xiong, Liuping Zhang, Qingshan Tian, Yongnan Fu, Wenjun Xiong

Abstract: Heart failure has always been a prevalent, disabling, and potentially life-threatening disease. For the treatment of heart failure, controlling cardiac remodeling is very important. In recent years, clinical trials have shown that sodium-glucose cotransporter-2 (SGLT-2) inhibitors not only excel in lowering glucose levels but also demonstrate favorable cardiovascular protective effects. However, the precise mechanisms behind the cardiovascular benefits of SGLT-2 inhibitors remain elusive. In this research, we assessed the impact of canagliflozin (CANA, an SGLT-2 inhibitor) on cardiac remodeling progression in mice and preliminarily elucidated the possible mechanism of action of the SGLT-2 inhibitor. Our results indicate that the administration of canagliflozin significantly attenuates myocardial hypertrophy and fibrosis and enhances cardiac ejection function in mice with isoprenaline (ISO)-induced cardiac remodeling. Notably, excessive mitophagy, along with mitochondrial structural abnormalities observed in ISO-induced cardiac remodeling, was mitigated by canagliflozin treatment, thereby attenuating cardiac remodeling progression. Furthermore, the differential expression of AMPK/PINK1/Parkin pathway-related proteins in ISO-induced cardiac remodeling was effectively reversed by canagliflozin, suggesting the therapeutic potential of targeting this pathway with the drug. Thus, our study indicates that canagliflozin holds promise in mitigating cardiac injury, enhancing cardiac function, and potentially exerting cardioprotective effects by modulating mitochondrial function and mitophagy through the AMPK/PINK1/Parkin pathway.

心力衰竭一直是一种常见病、致残性疾病,而且可能危及生命。对于心力衰竭的治疗,控制心脏重塑非常重要。近年来,临床试验表明,SGLT-2 抑制剂不仅能有效降低血糖水平,还能起到保护心血管的作用。然而,SGLT-2 抑制剂对心血管有益的确切机制仍不清楚。在目前的研究中,我们评估了卡格列净(CANA,一种 SGLT-2 抑制剂)对小鼠心脏重塑进展的影响,并初步阐明了 SGLT-2 抑制剂的可能作用机制。我们的研究结果表明,服用卡格列净可明显减轻异丙肾上腺素(ISO)诱导的小鼠心肌肥厚和纤维化,并增强心脏射血功能。值得注意的是,在 ISO 诱导的心脏重构中观察到的过度有丝分裂和线粒体结构异常在卡格列净治疗后得到缓解,从而减轻了心脏重构的进展。此外,在 ISO 诱导的心脏重构中,AMPK/PINK1/Parkin 通路相关蛋白的差异表达也被 canagliflozin 有效逆转,这表明以该通路为靶点的药物具有治疗潜力。因此,我们的研究表明,卡格列净有望通过AMPK/PINK1/Parkin通路调节线粒体功能和有丝分裂,从而减轻心脏损伤、增强心脏功能并发挥潜在的心脏保护作用。
{"title":"Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/Parkin Pathway to Alleviate ISO-induced Cardiac Remodeling.","authors":"Shaolin Gong, Yuan Sui, Mengxuan Xiao, Daoyao Fu, Zhiping Xiong, Liuping Zhang, Qingshan Tian, Yongnan Fu, Wenjun Xiong","doi":"10.1097/FJC.0000000000001625","DOIUrl":"10.1097/FJC.0000000000001625","url":null,"abstract":"<p><strong>Abstract: </strong>Heart failure has always been a prevalent, disabling, and potentially life-threatening disease. For the treatment of heart failure, controlling cardiac remodeling is very important. In recent years, clinical trials have shown that sodium-glucose cotransporter-2 (SGLT-2) inhibitors not only excel in lowering glucose levels but also demonstrate favorable cardiovascular protective effects. However, the precise mechanisms behind the cardiovascular benefits of SGLT-2 inhibitors remain elusive. In this research, we assessed the impact of canagliflozin (CANA, an SGLT-2 inhibitor) on cardiac remodeling progression in mice and preliminarily elucidated the possible mechanism of action of the SGLT-2 inhibitor. Our results indicate that the administration of canagliflozin significantly attenuates myocardial hypertrophy and fibrosis and enhances cardiac ejection function in mice with isoprenaline (ISO)-induced cardiac remodeling. Notably, excessive mitophagy, along with mitochondrial structural abnormalities observed in ISO-induced cardiac remodeling, was mitigated by canagliflozin treatment, thereby attenuating cardiac remodeling progression. Furthermore, the differential expression of AMPK/PINK1/Parkin pathway-related proteins in ISO-induced cardiac remodeling was effectively reversed by canagliflozin, suggesting the therapeutic potential of targeting this pathway with the drug. Thus, our study indicates that canagliflozin holds promise in mitigating cardiac injury, enhancing cardiac function, and potentially exerting cardioprotective effects by modulating mitochondrial function and mitophagy through the AMPK/PINK1/Parkin pathway.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"496-505"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kirenol Alleviates Inflammation and Oxidative Stress to Improve Myocardial Ischemia/Reperfusion Injury in Rats. Kirenol 可缓解炎症和氧化应激,从而改善大鼠心肌缺血再灌注损伤。
IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1097/FJC.0000000000001626
Jinlong Shi, Bingfeng Guan, Minghui Gong, Xinyi He

Abstract: Ischemic heart disease gravely threatens human health and even results in death. Kirenol is predominantly derived from the Herba Siegesbeckiae plant species and possesses a wide range of biological effects (such as antibacterial, anti-inflammatory, anticancer, and cardioprotective). However, the regulatory effects and associated mechanisms of kirenol in myocardial ischemia/reperfusion injury (MI/RI) remain unclear. In this study, first, the MI/RI rat model was established. It was demonstrated that kirenol protected against the aggravation of cardiac function in MI/RI rats. In addition, the inflammation was induced by ischemia reperfusion (IR), which was likewise affected by kirenol (5 or 10 mg/kg). Moreover, IR enhanced oxidative stress, a process that was counteracted by kirenol. Next, cell apoptosis was discovered to be heightened after IR, but this effect was neutralized by kirenol. Finally, it was revealed that kirenol has the ability to block the activation of the NF-κB pathway. In conclusion, it was disclosed that kirenol alleviated inflammation and oxidative stress through modulating the NF-κB pathway to improve MI/RI in rats. This work may offer novel insights for searching useful drugs for treating MI/RI.

缺血性心脏病严重威胁人类健康,甚至导致死亡。基瑞诺主要来源于豨莶草,具有广泛的生物效应(如抗菌、抗炎、抗癌和保护心脏)。然而,基仁醇在心肌缺血再灌注损伤(MI/RI)中的调节作用和相关机制仍不清楚。本研究首先建立了心肌缺血再灌注损伤大鼠模型。结果表明,基仑诺对 MI/RI 大鼠心功能的恶化有保护作用。此外,缺血再灌注(IR)会诱发炎症,而基萘酚(5 或 10 mg/kg)同样会影响炎症。此外,缺血再灌注增强了氧化应激,而基萘酚则抵消了这一过程。接着,研究发现红外线照射后细胞凋亡增加,但这种影响被基伦诺中和。最后,研究还发现,灭蚁灵能够阻止 NF-κB 通路的激活。总之,研究揭示了基瑞诺通过调节 NF-κB 通路缓解炎症和氧化应激,从而改善大鼠的 MI/RI 状况。这项研究为寻找治疗 MI/RI 的有效药物提供了新的思路。
{"title":"Kirenol Alleviates Inflammation and Oxidative Stress to Improve Myocardial Ischemia/Reperfusion Injury in Rats.","authors":"Jinlong Shi, Bingfeng Guan, Minghui Gong, Xinyi He","doi":"10.1097/FJC.0000000000001626","DOIUrl":"10.1097/FJC.0000000000001626","url":null,"abstract":"<p><strong>Abstract: </strong>Ischemic heart disease gravely threatens human health and even results in death. Kirenol is predominantly derived from the Herba Siegesbeckiae plant species and possesses a wide range of biological effects (such as antibacterial, anti-inflammatory, anticancer, and cardioprotective). However, the regulatory effects and associated mechanisms of kirenol in myocardial ischemia/reperfusion injury (MI/RI) remain unclear. In this study, first, the MI/RI rat model was established. It was demonstrated that kirenol protected against the aggravation of cardiac function in MI/RI rats. In addition, the inflammation was induced by ischemia reperfusion (IR), which was likewise affected by kirenol (5 or 10 mg/kg). Moreover, IR enhanced oxidative stress, a process that was counteracted by kirenol. Next, cell apoptosis was discovered to be heightened after IR, but this effect was neutralized by kirenol. Finally, it was revealed that kirenol has the ability to block the activation of the NF-κB pathway. In conclusion, it was disclosed that kirenol alleviated inflammation and oxidative stress through modulating the NF-κB pathway to improve MI/RI in rats. This work may offer novel insights for searching useful drugs for treating MI/RI.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"539-544"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial on: Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/PARKIN Pathway to Alleviate Isoprenaline-Induced Cardiac Remodeling. 社论:卡格列净通过 AMPK/PINK1/PARKIN 通路介导有丝分裂,减轻异丙肾上腺素诱导的心脏重构。
IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1097/FJC.0000000000001629
Alfredo Caturano, Davide Nilo, Roberto Nilo, Vincenzo Russo, Marcellino Monda, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso
{"title":"Editorial on: Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/PARKIN Pathway to Alleviate Isoprenaline-Induced Cardiac Remodeling.","authors":"Alfredo Caturano, Davide Nilo, Roberto Nilo, Vincenzo Russo, Marcellino Monda, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso","doi":"10.1097/FJC.0000000000001629","DOIUrl":"10.1097/FJC.0000000000001629","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"490-492"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erectile Dysfunction Risk Among Patients With Diabetes Mellitus Using Sodium-Glucose Cotransporter 2 Inhibitors. 使用钠-葡萄糖共转运体 2 抑制剂的糖尿病患者出现勃起功能障碍的风险。
IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1097/FJC.0000000000001624
Wei-Syun Hu, Cheng-Li Lin

Abstract: The aim of this study was to explore the incidence of new-onset erectile dysfunction (ED) in diabetes mellitus (DM) patients with sodium-glucose cotransporter 2 inhibitors (SGLT2I) use compared with a control group of non-SGLT2I use by propensity score matching approach. Cox proportional hazards regression models were used to examine the effect of SGLT2I and risk factors on the risk of developing ED, presented as a hazard ratio with a 95% confidence interval. One lakhs fifty nine thousand seven hundred seventy three patients with DM using SGLT2I and 159,773 propensity score matching patients with DM who had never used SGLT2I were included. SGLT2I users had a higher risk of ED than the non-SGLT2I users (adjusted hazard ratio = 1.55, 95% confidence interval = 1.40-1.72). The likelihood of developing ED was higher in patients with SGLT2I use was found.

通过倾向匹配(PS)方法,探讨使用钠-葡萄糖共转运体2抑制剂(SGLT2I)的糖尿病(DM)患者与未使用SGLT2I的对照组相比,新发勃起功能障碍(ED)的发生率。采用 Cox 比例危险度回归模型来检验 SGLT2I 和风险因素对罹患 ED 风险的影响,结果显示为危险比 (HR) 和 95% 置信区间 (CI)。共纳入了 159773 名使用 SGLT2I 的 DM 患者和 159773 名从未使用过 SGLT2I 的 PS 匹配 DM 患者。与未使用 SGLT2I 的患者相比,使用 SGLT2I 的患者发生 ED 的风险更高(调整后 HR = 1.55,95% CI = 1.40-1.72)。研究发现,使用 SGLT2I 的患者发生 ED 的可能性更高。
{"title":"Erectile Dysfunction Risk Among Patients With Diabetes Mellitus Using Sodium-Glucose Cotransporter 2 Inhibitors.","authors":"Wei-Syun Hu, Cheng-Li Lin","doi":"10.1097/FJC.0000000000001624","DOIUrl":"10.1097/FJC.0000000000001624","url":null,"abstract":"<p><strong>Abstract: </strong>The aim of this study was to explore the incidence of new-onset erectile dysfunction (ED) in diabetes mellitus (DM) patients with sodium-glucose cotransporter 2 inhibitors (SGLT2I) use compared with a control group of non-SGLT2I use by propensity score matching approach. Cox proportional hazards regression models were used to examine the effect of SGLT2I and risk factors on the risk of developing ED, presented as a hazard ratio with a 95% confidence interval. One lakhs fifty nine thousand seven hundred seventy three patients with DM using SGLT2I and 159,773 propensity score matching patients with DM who had never used SGLT2I were included. SGLT2I users had a higher risk of ED than the non-SGLT2I users (adjusted hazard ratio = 1.55, 95% confidence interval = 1.40-1.72). The likelihood of developing ED was higher in patients with SGLT2I use was found.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"545-549"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium-Glucose Cotransporter 2 Inhibitors, Malnutrition, Cachexia, and Survival in Patients With Heart Failure With a History of Anthracycline Treatment. 有蒽环类药物治疗史的心衰患者的 SGLT2 抑制剂、营养不良、恶病质和存活率。
IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1097/FJC.0000000000001620
Benjamin D Henson, Claudia A Bale-Neary, Ryan Mecaskey, Ogechi Gbujie, Michelle Zhan, Krishnasree Rao, Salvatore Carbone

Abstract: Patients undergoing anthracycline-based cancer treatments have an increased risk of heart failure or worsening preexisting heart failure as well as adverse metabolic outcomes such as malnutrition and cachexia. This retrospective study explored the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on these outcomes in patients with heart failure previously treated with anthracyclines. Using the TriNetX research network, we identified 1545 patients with a history of SGLT2i use and 17,681 patients without a history of SGLT2i use. We then performed 1:1 propensity score matching resulting in 1323 patients within each cohort. Patients were analyzed over a 5-year period. SGLT2i use was associated with significantly reduced risks of cachexia {hazard ratio (HR) 0.453, 95% confidence interval (CI) [0.286-0.718]}, malnutrition (HR 0.702, 95% CI [0.547-0.900]), adult failure to thrive (HR 0.489, 95% CI [0.345-0.693]), and all-cause mortality (HR 0.490, 95% CI [0.423-0.568]). These findings call for additional research to determine whether SGLT2i may indeed improve nutritional status and survival in patients with heart failure receiving anthracycline therapy.

接受蒽环类癌症治疗的患者发生心力衰竭(HF)和不良代谢结果(如营养不良和恶病质)的风险会增加。这项回顾性研究探讨了钠-葡萄糖协同转运体 2 抑制剂(SGLT2i)对既往接受过蒽环类药物治疗的心力衰竭患者上述结果的影响。通过 TriNetx 研究网络,我们确定了 1,545 名有 SGLT2i 使用史的患者和 17,681 名无 SGLT2i 使用史的患者。然后,我们进行了 1:1 倾向评分匹配,结果每个队列中都有 1323 名患者。我们对患者进行了为期 5 年的分析。使用 SGLT2i 可显著降低恶病质(HR 0.453,95% CI [0.286-0.718])、营养不良(HR 0.702,95% CI [0.547-0.900])、成人发育不良(HR 0.489,95% CI [0.345-0.693])和全因死亡率(HR 0.490,95% CI [0.423-0.568])的风险。这些发现要求开展更多研究,以确定 SGLT2i 是否确实能改善接受蒽环类疗法患者的营养状况和生存率。
{"title":"Sodium-Glucose Cotransporter 2 Inhibitors, Malnutrition, Cachexia, and Survival in Patients With Heart Failure With a History of Anthracycline Treatment.","authors":"Benjamin D Henson, Claudia A Bale-Neary, Ryan Mecaskey, Ogechi Gbujie, Michelle Zhan, Krishnasree Rao, Salvatore Carbone","doi":"10.1097/FJC.0000000000001620","DOIUrl":"10.1097/FJC.0000000000001620","url":null,"abstract":"<p><strong>Abstract: </strong>Patients undergoing anthracycline-based cancer treatments have an increased risk of heart failure or worsening preexisting heart failure as well as adverse metabolic outcomes such as malnutrition and cachexia. This retrospective study explored the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on these outcomes in patients with heart failure previously treated with anthracyclines. Using the TriNetX research network, we identified 1545 patients with a history of SGLT2i use and 17,681 patients without a history of SGLT2i use. We then performed 1:1 propensity score matching resulting in 1323 patients within each cohort. Patients were analyzed over a 5-year period. SGLT2i use was associated with significantly reduced risks of cachexia {hazard ratio (HR) 0.453, 95% confidence interval (CI) [0.286-0.718]}, malnutrition (HR 0.702, 95% CI [0.547-0.900]), adult failure to thrive (HR 0.489, 95% CI [0.345-0.693]), and all-cause mortality (HR 0.490, 95% CI [0.423-0.568]). These findings call for additional research to determine whether SGLT2i may indeed improve nutritional status and survival in patients with heart failure receiving anthracycline therapy.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"486-489"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interleukin-1 blockade with RPH-104 (goflikicept) in patients with ST-segment elevation myocardial infarction (STEMI): secondary endpoints from an international, double blind, randomized, placebo-controlled, phase IIa study. RPH-104(gofikicept)对 ST 段抬高型心肌梗死(STEMI)患者的白细胞介素-1 阻断作用:一项国际双盲、随机、安慰剂对照 IIa 期研究的次要终点。
IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-02 DOI: 10.1097/FJC.0000000000001635
Antonio Abbate, Benjamin Van Tassell, Vlad Bogin, Roshanak Markley, Dmitry V Pevzner, Paul C Cremer, Imad A Meray, Dmitry V Privalov, Angela Taylor, Sergey A Grishin, Alina N Egorova, Ekaterina G Ponomar, Yan Lavrovsky, Mikhail Yu Samsonov

In a randomized double-blinded clinical trial of patients with ST segment elevation myocardial infarction (STEMI), goflikicept, an Interleukin-1 (IL-1) blocker, significantly reduced systemic inflammation, measured as the area-under-the-curve (AUC) for high-sensitivity C reactive protein (hsCRP) at 14 days. We report secondary analyses of biomarkers at 28 days, and cardiac function and clinical endpoints at 1 year. Patients received a single administration of goflikicept 80 mg (n=34), goflikicept 160 mg (n=34), or placebo (n=34). Both doses of goflikicept significantly reduced the AUC for hsCRP at 28 days compared with placebo, without statistically significant differences between the doses. There we no statistically significant differences between groups in the AUC for natriuretic peptides at 28 days. There were no significant differences between placebo, goflikicept 80 mg and 160 mg groups in deaths (2.9%, 2.9% and 0%), hospitalization for cardiovascular reasons (9.1%, 5.9%, and 0%), new-onset or progression of heart failure (9.1%, 5.9%, and 5.9%), and new or increased use of loop diuretics (24.2%, 14.7%, and 17.6%), nor in the number of patients with treatment emergent adverse events, with no treatment-related serious adverse events in any group. In conclusion, in patients with STEMI, IL-1 blockade with goflikicept 80 mg or 160 mg was well tolerated and associated with significant reduction of systemic inflammation. Further adequately powered studies are warranted to determine whether the reduction in systemic inflammation with goflikicept translates into a clinical benefit in patients with STEMI.

在一项针对ST段抬高型心肌梗死(STEMI)患者的随机双盲临床试验中,白细胞介素-1(IL-1)阻断剂gofikicept显著降低了全身炎症,14天时的测量值为高敏C反应蛋白(hsCRP)的曲线下面积(AUC)。我们报告了对 28 天的生物标志物以及 1 年的心脏功能和临床终点的二次分析。患者单次服用高飞蓟素 80 毫克(34 人)、高飞蓟素 160 毫克(34 人)或安慰剂(34 人)。与安慰剂相比,两种剂量的goflikicept都能在28天时显著降低hsCRP的AUC,但不同剂量之间无统计学差异。28天时,钠尿肽的AUC在组间无明显统计学差异。在死亡(2.9%、2.9% 和 0%)、因心血管原因住院(9.1%、5.9% 和 0%)、新发心力衰竭或心力衰竭恶化(9.1%、5.9% 和 0%)方面,安慰剂组、gofikicept 80 毫克组和 160 毫克组之间无明显差异。1%、5.9% 和 5.9%),以及新使用或增加使用襻利尿剂(24.2%、14.7% 和 17.6%)。总之,在 STEMI 患者中,使用戈氟西肽 80 毫克或 160 毫克阻断 IL-1 的耐受性良好,并能显著减轻全身炎症反应。有必要进一步开展充分的研究,以确定戈氟西普对全身炎症的减轻是否会转化为 STEMI 患者的临床获益。
{"title":"Interleukin-1 blockade with RPH-104 (goflikicept) in patients with ST-segment elevation myocardial infarction (STEMI): secondary endpoints from an international, double blind, randomized, placebo-controlled, phase IIa study.","authors":"Antonio Abbate, Benjamin Van Tassell, Vlad Bogin, Roshanak Markley, Dmitry V Pevzner, Paul C Cremer, Imad A Meray, Dmitry V Privalov, Angela Taylor, Sergey A Grishin, Alina N Egorova, Ekaterina G Ponomar, Yan Lavrovsky, Mikhail Yu Samsonov","doi":"10.1097/FJC.0000000000001635","DOIUrl":"10.1097/FJC.0000000000001635","url":null,"abstract":"<p><p>In a randomized double-blinded clinical trial of patients with ST segment elevation myocardial infarction (STEMI), goflikicept, an Interleukin-1 (IL-1) blocker, significantly reduced systemic inflammation, measured as the area-under-the-curve (AUC) for high-sensitivity C reactive protein (hsCRP) at 14 days. We report secondary analyses of biomarkers at 28 days, and cardiac function and clinical endpoints at 1 year. Patients received a single administration of goflikicept 80 mg (n=34), goflikicept 160 mg (n=34), or placebo (n=34). Both doses of goflikicept significantly reduced the AUC for hsCRP at 28 days compared with placebo, without statistically significant differences between the doses. There we no statistically significant differences between groups in the AUC for natriuretic peptides at 28 days. There were no significant differences between placebo, goflikicept 80 mg and 160 mg groups in deaths (2.9%, 2.9% and 0%), hospitalization for cardiovascular reasons (9.1%, 5.9%, and 0%), new-onset or progression of heart failure (9.1%, 5.9%, and 5.9%), and new or increased use of loop diuretics (24.2%, 14.7%, and 17.6%), nor in the number of patients with treatment emergent adverse events, with no treatment-related serious adverse events in any group. In conclusion, in patients with STEMI, IL-1 blockade with goflikicept 80 mg or 160 mg was well tolerated and associated with significant reduction of systemic inflammation. Further adequately powered studies are warranted to determine whether the reduction in systemic inflammation with goflikicept translates into a clinical benefit in patients with STEMI.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antithrombotic Treatment Regimens in Patients Undergoing Percutaneous Coronary Revascularization Requiring Oral Anticoagulation: What Real-World Evidence Shows Us. 需要口服抗凝药的经皮冠状动脉血运重建术患者的抗血栓治疗方案:真实世界的证据告诉我们什么。
IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1097/FJC.0000000000001619
Marco Giuseppe Del Buono, Giulia La Vecchia, Dominck J Angiolillo
{"title":"Antithrombotic Treatment Regimens in Patients Undergoing Percutaneous Coronary Revascularization Requiring Oral Anticoagulation: What Real-World Evidence Shows Us.","authors":"Marco Giuseppe Del Buono, Giulia La Vecchia, Dominck J Angiolillo","doi":"10.1097/FJC.0000000000001619","DOIUrl":"10.1097/FJC.0000000000001619","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"391-393"},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Cardiovascular Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1